BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30305604)

  • 1. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota.
    Dong M; Meng Z; Kuerban K; Qi F; Liu J; Wei Y; Wang Q; Jiang S; Feng M; Ye L
    Cell Death Dis; 2018 Oct; 9(10):1039. PubMed ID: 30305604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 4. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
    Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
    Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
    Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
    PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody.
    Tej GNVC; Neogi K; Nayak PK
    Int Immunopharmacol; 2019 Dec; 77():106002. PubMed ID: 31711939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
    Kaplanov I; Carmi Y; Kornetsky R; Shemesh A; Shurin GV; Shurin MR; Dinarello CA; Voronov E; Apte RN
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1361-1369. PubMed ID: 30545915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model.
    Chen G; Cao Z; Shi Z; Lei H; Chen C; Yuan P; Wu F; Liu C; Dong M; Song Y; Zhou J; Lu Y; Zhang L
    Biomed Pharmacother; 2021 Aug; 140():111542. PubMed ID: 34088571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin facilitates anti-PD-L1 efficacy through the regulation of intestinal microbiota.
    Zhao X; Liu C; Peng L; Wang H
    Genes Immun; 2024 Feb; 25(1):7-13. PubMed ID: 38092885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
    Ngiow SF; von Scheidt B; Akiba H; Yagita H; Teng MW; Smyth MJ
    Cancer Res; 2011 May; 71(10):3540-51. PubMed ID: 21430066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
    Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.